Gyre Therapeutics files Cullgen financials for merger; Cullgen FY2025 net loss $10.8M

GYRE THERAPEUTICS, INC.

Cullgen FY2025 net loss $10.8M, accumulated deficit $132.2M as of Dec 31, 2025.
Cullgen revenue $15.4M from collaboration; R&D expense $19.3M, G&A $10.2M.
Cullgen had $40.2M in cash and short-term investments; total assets $53.6M.
Redeemable convertible preferred stock $173.5M; stockholders' deficit $127.4M.
Merger closed May 4, 2026; this amendment provides required financial statements.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.